Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine

Journal of Infectious Diseases

Volumn 181, Issue 3, 2000, Pages 904-911

  Hanna, George J ^a,b   Johnson, Victoria A ^c   Kuritzkes, Daniel R ^d   Richman, Douglas D ^e   Leigh Brown, Andrew J ^f   Savara, Anu V ^a   Hazelwood, J Darren ^c   D'Aquila, Richard T ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CROSS RESISTANCE; GENE MUTATION; GENETIC SELECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION; VIRUS RESISTANCE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; CODON; DIDANOSINE; DOUBLE-BLIND METHOD; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MUTATION; NEVIRAPINE; POLYMERASE CHAIN REACTION; ZIDOVUDINE;

EID: 0034081772     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315329     Document Type: Article

References (33)

1. 1. Shafer RW, Kozal MJ, Winters MA, et al. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J Infect Dis 1994; 169:722-9.
2. 2. Shirasaka T, Kavlick MF, Ueno T, et al. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci USA 1995; 92:2398-402.
3. 3. Winters MA, Coolley KL, Girard YA, et al. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J Clin Invest 1998; 102:1769-75.
4. 4. Richman DD, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994; 68:1660-6.
5. 5. Macarthur RD, Kosmyna JM, Crane LR, Kovari L. The presence or absence of zidovudine in a nevirapine-containing antiretroviral regimen determines which of two nevirapine-limiting mutations occurs on virologic failure [abstract 1171]. In: Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1999:494-5.
6. 6. Larder BA. 3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 1992; 36:2664-9.
7. 7. Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 1993; 90:5653-6.
8. 8. St. Clair MH, Martin JL, Tudor-Williams G, et al. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991; 253:1557-9.
9. 9. Holodniy M, Mole L, Margolis D, et al. Determination of human immunodeficiency virus RNA in plasma and cellular viral DNA genotypic zidovudine resistance and viral load during zidovudine-didanosine combination therapy. J Virol 1995; 69:3510-6.
10. 10. Department of Health and Human Services, Henry J. Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR Morb Mortal Wkly Rep 1998; 47:43-82.
11. 11. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society - USA Panel. JAMA 1998; 280:78-86.
12. 12. Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial (Italy, The Netherlands, Canada, and Australia Study). JAMA 1998; 279:930-7.
13. 13. D'Aquila RT, Hughes MD, Johnson VA, et at. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Ann Intern Med 1996; 124:1019-30.
14. 14. Leigh Brown AJ, Gunthard HF, Wong JK, et al. Sequence clusters in human immunodeficiency virus type 1 reverse transcriptase are associated with subsequent virological response to antiretroviral therapy. J Infect Dis 1999; 180:1043-9.
15. + lymphocyte count improves assessment of antiretroviral therapeutic response: ACTG 241 Protocol Virology Sub-study Team. Ann Intern Med 1997; 126:929-38.
16. 16. Division of AIDS, National Institutes of Health (online). Virology manual for HIV laboratory, 1997 (http://www.niaid.nih.gov/daids/vir_manual/).
17. 17. Gunthard HF, Wong JK, Ignacio CC, Havlir DV, Richman DD. Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples. AIDS Res Hum Retroviruses 1998; 14:869-76.
18. 18. Kozal MJ, Shah N, Shen N, et al. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med 1996; 2:753-9.
19. 19. Gunthard HF, Leigh-Brown AJ, D'Aquila RT, et al. Higher selection pressure from antiretroviral drugs in vivo results in increased evolutionary distance in HIV-1 pol. Virology 1999; 259:154-65.
20. 20. Schinazi RF, Larder BA, Mellors JW. Resistance table: mutations in retroviral genes associated with drug resistance. Int Antiviral News 1997; 5:129-42.
21. 21. Larder B. New insights into genetic mechanisms of HIV drug resistance [abstract S34]. In: Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 1999:218.
22. 22. Johnson V, Saag M, Decker J, et al. Viral resistance in adults treated with nevirapine (NVP) added to established nucleoside RT Inhibitor regimens of ZDV + ddC, ZDV + ddI, or ddI alone [abstract 70]. In: Proceedings of the Third International HIV Drug Resistance Workshop (Kauai, Hawaii), 1994
23. 23. Bacheler L, Weislow O, Snyder S, Hanna G, D'Aquila R. Virologic resistance to efavirenz [abstract 41213]. In: Conference record of the 12th International Conference on AIDS (Geneva). Stockholm, Sweden: International AIDS Society, 1998:784.
24. 24. Kozal MJ, Shafer RW, Winters MA, Katzenstein DA, Merigan TC. A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J Infect Dis 1993; 167:526-32.
25. 25. Gingeras TR, Prodanovich P, Latimer T, Guatelli JC, Richman DD, Barringer KJ. Use of self-sustained sequence replication amplification reaction to analyze and detect mutations in zidovudine-resistant human immunodeficiency virus. J Infect Dis 1991; 164:1066-74.
26. th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 1998:211.
27. 27. Fujiwara T, Sato A, el-Farrash M, et al. S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1998; 42:1340-5.
28. 28. Young SD, Britcher SF, Tran LO, et al. L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1995; 39:2602-5.
29. 29. Bloor S, Hertogs K, De Vroey V, Miller V, Sturmer M, Larder B. Lamivudine-resistant HIV-1 clinical isolates lacking the Met184Val mutation have novel polymorphisms in RT [abstract 25]. Antiviral Ther 1999; 4(Suppl 1):19-20.
30. 30. Precious HM, Gunthard HF, Wong JK, et al. Multiple sites in HIV-1 reverse transcriptase associated with virological response to combination therapy. AIDS 2000; 14:31-6.
31. 31. Kellam P, Boucher CA, Larder BA. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci USA 1992; 89: 1934-8.
32. 32. Gao Q, Gu Z, Parniak MA, et al. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1993; 37: 1390-2.
33. 33. Lacey SF, Larder BA. Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2′,3′-didehydro-2′,3′-dideoxythymidine in cell culture. Antimicrob Agents Chemother 1994; 38: 1428-32.